<DOC>
	<DOCNO>NCT01971970</DOCNO>
	<brief_summary>Anti-TNF treatment ( infliximab ( IFX ) , adalimumab ( ADA ) ) become standard therapy refractory pediatric adult Crohn 's disease ( CD ) patient , use induction ( primary response ) maintenance remission . When effective , clinical endoscopic remission reach within week . However , primary non-response observe 20 % pediatric patient , 40 % adult CD patient , suggest robust acute response anti-TNF therapy child compare adults.During maintenance treatment , 60 - 80 % patient secondary loss response , necessitate dose adjustment maintain clinical response . Anti-TNF treatment also increasingly used ulcerative colitis ( UC ) , show induce remission active disease . For UC , comparison efficacy child versus adult difficult report study child scarce . Anti-TNF treatment associate rare potentially fatal side effect , infusion reaction , expensive treatment . To avoid overtreatment necessary early identify non-responders treatment , therefore important develop predictive biomarkers treatment response .</brief_summary>
	<brief_title>Biomarkers Anti-TNF Treatment IBD</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>AntiTNF naïve CD patient ( ≥ 6 year ) initiate antiTNF treatment ( IFX ADA ) active luminal disease , fail treatment immunomodulators ( azathioprine , 6mercaptopurine , methotrexate ) corticosteroid . AntiTNF naïve UC patient ( ≥ 6 year ) initiate antiTNF treatment ( IFX ADA ) active disease despite corticosteroid treatment fail immunomodulator treatment . AntiTNF naïve CD UC patient ( ≥ 6 year ) initiate antiTNF treatment ( IFX ADA ) intolerance treatment immunomodulators ( azathioprine , 6mercaptopurine , methotrexate ) corticosteroid . Informed consent patient parent ( require ) . IBD patient initiate IFX ADA immediately diagnosis . Presence severe perianal disease primary indication start antiTNF treatment . Age &lt; 6 year antiTNF maintenance treatment initiate .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adult</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Anti-TNF response</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Adalimumab</keyword>
</DOC>